SecBot SecBot
8-K ·Filed Jul 13, 2026

ONCY

ONCOLYTICS BIOTECH INC
NEUTRAL
Impact 4/10
Horizonmonths Processed4mo ago SEC0001129928-26-000043
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

Monitor the outcome of the Type D FDA meeting in August 2026 for clarity on the registrational path. The year-end 2026 Part A tumor response data will be the next key catalyst. Until then, the stock is likely to trade on trial execution milestones and broader biotech sentiment.

DirectionNeutral
Confidencemedium
Horizonmonths

pelareorep

◆ Mixed Named in this 8-K
Impact
Phase
Phase 2/3
Time to market
At least 3-5 years (Phase 3 just launching; no BLA/NDA filed)
Next catalyst
None dated

What to watchOncolytics is a single-asset clinical-stage biotech with no approved products. The stock trades at ~$0.92 against a mean analyst price target of ~$4.94 (~5x upside), but the company has limited cash (~$12.4M as of Q3 2025) and has tapped a $75M ATM facility, significant dilution risk. Watch for the Phase 3 pancreatic cancer trial launch (H1 2026) and any anal cancer registration updates, but do not expect a near-term binary catalyst.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.9289
T+0 close · Jul 13, 2026 · via day close
Latest settled
−35.62%
T+60 · $0.5980
Vs SPY
−39.62%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 13 $0.9289entry
  2. T+1 · 4mo ago −2.23%α −2.58% · $0.9082
  3. T+5 · 4mo ago −8.14%α −7.35% · $0.8533
  4. T+20 · 3mo ago −13.58%α −16.76% · $0.8028
  5. T+60 · 6w ago −35.62%α −39.62% · $0.5980
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Oncolytics Biotech provided a clinical and regulatory update on its REO 033 study in RAS-mutant MSS colorectal cancer, reporting that half of planned clinical sites will be activated by end of July with over 20 patients pre-identified. The company will hold a Type D meeting with the FDA in early August 2026 to discuss adding a registrational Part B to the study, which could support accelerated and full approval. Initial tumor response data from Part A is expected by year-end 2026, with Part B enrollment potentially starting Q1 2027.

Key Facts

  • Half of planned clinical sites for REO 033 will be activated by end of July 2026; over 20 patients pre-identified across centers.
  • Type D meeting with FDA scheduled for first half of August 2026 to discuss registrational expansion via Part B of REO 033.
  • Part B designed as a randomized study with blinded independent central review to support potential accelerated and full approval.
  • Initial tumor response update from Part A expected by year-end 2026; Part B enrollment targeted for Q1 2027 subject to FDA feedback.
  • Pelareorep has Fast Track designation from FDA for colorectal cancer indication.

Financial Impact

No financial figures reported; filing is a clinical and regulatory update with no revenue or cost disclosures.

Risk Factors

  • FDA may not agree to the proposed registrational design, delaying or altering the pathway.
  • Clinical trial enrollment or data may disappoint, particularly given the challenging RAS-mutant MSS CRC indication.
  • Company is pre-revenue and may require additional financing to complete the expanded study.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
75% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001129928-26-000043
Document: oncolyticsreo033update.htm0001129928-26-000043
Document: 0001129928-26-000043-index-headers.html0001129928-26-000043
Document: 0001129928-26-000043-index.html0001129928-26-000043
Document: 0001129928-26-000043.txt0001129928-26-000043

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 13, 2026